Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.

@article{Tabata1999AntiangiogenicRO,
  title={Antiangiogenic radioimmunotherapy of human solid tumors in SCID mice using (125)I-labeled anti-endoglin monoclonal antibodies.},
  author={Masahiro Tabata and Masami Kondo and Yuro Haruta and Ben K. Seon},
  journal={International journal of cancer},
  year={1999},
  volume={82 5},
  pages={737-42}
}
Endoglin (CD105), which is a component of the TGF-beta receptor complex, is highly expressed at the surface of proliferating human endothelial cells such as those of tumor vessels. In the present study, we tested the antitumor efficacy of (125)I-labeled anti-endoglin monoclonal antibodies (MAbs), SN6f and SN6j, against s. c. tumors of MCF-7 human breast cancer cells in SCID mice by i.v. administration. SN6f and SN6j cross-react weakly with mouse endothelial cells, but show no significant… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105

Cancer Immunology, Immunotherapy • 2011
View 5 Excerpts
Highly Influenced

TGF-β in Human Disease

Springer Japan • 2013
View 2 Excerpts

Similar Papers

Loading similar papers…